Prostate cancer (PCA) is a major health concern in current times. Ever since prostate
specific antigen (PSA) was introduced in clinical practice almost three decades ago, the …

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most
patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …

Prostate cancer is the fifth leading cause of cancer death worldwide and biomarkers with
improved specificity and sensitivity are in urgent need for precise prognosis and diagnose …

Due to its significant applicability for early detection, risk prediction and follow-up evaluation,
prostate specific antigen (PSA) has revolutionized our ability to treat prostate cancer …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …

INTRODUCTION: Due to its universal applicability for early detection and prediction of
cancer stage and disease recurrence, widespread implementation of serum-based prostate …

Traditionally, diagnosis and staging of prostate cancer (PCa) have been based on prostate-
specific antigen (PSA) level, digital rectal examination (DRE), and transrectal ultrasound …

Prostate cancer is the most prevalent cancer in men and can be managed effectively if
diagnosed early and monitored. Currently, prostate-specific antigen testing in conjunction …

Worldwide, prostate cancer (PC) is the second-most-frequently diagnosed male cancer and
the fifth-most-common cause of all cancer-related deaths. Suspicion of PC in a patient is …

Prostate cancer is the most noncutaneous malignancy diagnosed in men in the USA. The
discovery of prostate-specific antigen (PSA) revolutionized prostate cancer diagnosis and …